API version 2026-10-21 is now available. The Claude API has evolved a lot, but this is our first official version release since 2023. We plan to release versions more often so you can handle breaking changes before a new model requires them. 2023-06-01 is not deprecated.

With Intelligent UI, GPT‑6 can now compose responses using text, visuals, and interactive elements, choosing how they fit together based on your question. Responses can include graphics and charts to help explain an idea, along with tappable buttons, forms, and interactive experiences you can use directly in your conversation.

Reset all propagated. Enjoy.

JUST IN: Trump reportedly asked Grok how Venezuelans would react if the U.S. captured Nicolás Maduro weeks before ordering the mission, with the AI predicting many would celebrate his downfall.

Today we announced the Claude-led discovery of a molecular machine that we suspect could represent a new gene editing mechanism. Its precise function, biotechnological utility (if any), or level of significance is not yet clear, but at minimum it is work I would have been proud to do as a PhD student. The work was done mostly, though not entirely, by Claude: our life sciences team suggested a broad area of research, Claude read through the literature and a bunch of genome data and discovered something interesting, then Claude proposed experiments to verify the discovery and our team carried them out. It’s easy to dismiss this as a one-off or curiosity, but we’ve repeatedly seen a pattern where AI performance in new intellectual domains goes from weak to superhuman in a matter of a few years. In 2023 models struggled to do math at the level of an average high-school student. In 2024 they started to do well on math competitions for the best high-schoolers in the country, in 2025 they started to solve minor open problems, in early 2026 more significant open problems, and in late 2026 they are beginning to solve the top few open problems in all of mathematics. We believe AI for biology is on a similar exponential trend. The main difference between biology and mathematics, of course, is that math can be done purely theoretically, while biology requires experimentation. Some have used this to draw the conclusion that AI’s utility in biology will be limited. We think this is wrong. As we’ve demonstrated today, humans can collaborate with AI to perform the experiments, validate key results in a few weeks and, if necessary, work with the AI to iterate on what they find. Eventually it may even be possible for Claude itself to safely perform the experiments by autonomously controlling lab equipment, with appropriate safeguards in place, but we aren’t doing that today (our lab is also a BSL1/BSL2 facility that doesn't handle materials dangerous to humans). More broadly, biomedical advancement has many stages — from fundamental biology discoveries, to translational research, to drug discovery, clinical trials, and finally the actual delivery of medicines and health care to patients. We are also interested in these later stages, but even simply accelerating the first stage of fundamental biological discoveries has the potential to speed up and broaden the entire pipeline. Improving our understanding of biology and sharpening biologists’ tools can drive forward all of the later stages, for example by identifying new drug targets, finding new therapeutic modalities, allowing for more precise measurement, and speeding up the experimental loop which itself further accelerates our understanding of biology. This will not in itself speed up clinical trial times, but if it succeeds it could greatly increase the number of promising candidates that go into the pipeline — an increase in throughput even though latency remains. In Machines of Loving Grace, I wrote about AI’s potential to “cure most diseases in 5-10 years” — a goal that sounds impossible, but one I believe is just barely possible if AI is applied to every stage of the pipeline. The first step is showing that AI can first help with, and then drive, biological discoveries. Claude’s discovery is the latest in a line of related prior work that goes back decades, beginning with systems like CRISPR, and continuing with discoveries like the bridge recombinase and VIPR in the past few years. Recently, there has been heightened interest in systems based on reverse transcriptase (RT) enzymes, the enzyme underlying the system Claude identified. And most recently, a Stanford team working independently described a novel RT system with an associated non-coding array that is in some ways similar to the one Claude found, though they are distinct systems that evolved independently from each other. I believe that we’re at the very beginning of finding such systems and developing them into powerful tools for biotechnology. I’m proud of the resources Anthropic has invested in accelerating the public benefits of AI through the life sciences, and we’re aiming both to grow our life sciences team and to work with other scientists to extend this approach to a broad range of problems. If you have a proposal for a research collaboration or are interested in joining our life sciences team, please reach out.

Nearly half a year of silence. We spent it studying one problem: how far RL can scale. MiMo-V2.6 is in the middle of its RL run right now. Three things we scaled: compute (~2B tokens per step, 1568 prompts × 16 rollouts, fully async), environments and harnesses (multi-task agentic RL, mixed across multiple harnesses in one run), and grader compute (agentic in-group credit assignment, with test-case and rubric-based rewards). We'll open-source the details piece by piece over the coming weeks. Streaming the run: mimo.xiaomi.com/rl/

OK nevermind, the team and Astra did a good job and our systems are more scalable than we anticipated. Astra is now rolled out to all Plus and Business users too. Hope you have a blast and let us know how it goes!

A good thing about having aged is that I feel that it’s been 20 years since I’ve pressed the reset button. Intrigued to see if I can find it tomorrow and dust it up

🚨 BREAKING: The 5 hour limit for ChatGPT Work/Codex returns tomorrow for Plus subscribers (not Pro yet)

Reset will land around 14pm PST tomorrow.

can't wait to see how many tasks I can get out of GPT-5.6 Sol Max today in the ChatGPT desktop app once Tibo's banked usage reset drops Yesterday, I got 1 task done in Pi, 3 in ChatGPT app before my weekly limit was reached Today, I'll be using solely the ChatGPT desktop app

hope this is opus 5! 👀 though, if it ends up being on-par with GPT-5.6 Sol, it'll be awkward af if OpenAI does end up releasing GPT-6 at the end of the month...

Introducing Claude Sonnet 5, our most agentic Sonnet yet. It makes plans, uses tools like browsers and terminals, and runs autonomously at a level that just a few months ago required larger and more expensive models.